What is the price-to-earnings ratio of Abliva?
The price-earnings ratio of Abliva is currently -1.68.
Abliva P/E 2024
Abliva P/E
-1.68
Ticker
ABLI.ST
ISIN
SE0002575340
WKN
A0X93Z
As of Jul 31, 2024, Abliva's P/E ratio was -1.68, a -32.8% change from the -2.5 P/E ratio recorded in the previous year.
The Abliva P/E history
Abliva Aktienanalyse
What does Abliva do?
The company Abliva AB is a biopharmaceutical company specializing in the development of drugs for the treatment of rare diseases and neurological disorders. The company was founded in 2004 and is headquartered in Stockholm, Sweden. Business Model Abliva AB is an emerging company that focuses on the development of drugs for the treatment of rare diseases and neurological disorders. The company works closely with academic research groups, universities, and other companies to develop innovative therapies that meet the needs of patients. Abliva has a pipeline of promising products at various stages of clinical development. The company also has a strong partnership with Karolinska Institutet, a leading medical university in Sweden, to support its research and development activities. Products Abliva specializes in the development of drugs for the treatment of rare diseases. The company has several promising products in its pipeline that are in various stages of clinical development. Additionally, the company has an extensive research and development department that constantly explores and develops new therapeutic options for rare diseases and neurological disorders. One of Abliva's most promising products is a compound called KL1333, which is being developed for the treatment of mitochondrial diseases. KL1333 is a novel drug that aims to improve mitochondrial function and thereby improve the symptoms of mitochondrial diseases. The drug is currently in Phase IIb of development. Another promising product from Abliva is a compound called NV354, which is being developed for the treatment of neuroinflammatory diseases such as multiple sclerosis (MS). NV354 is an innovative compound that inhibits the overactivity of the immune system and reduces inflammation in the nervous system. The drug is currently in the preclinical phase of development. Abliva also has a range of products in development that focus on other neurological disorders such as Parkinson's, Huntington's, and Alzheimer's. Divisions Abliva operates in three main areas: research and development, clinical trials, and commercial development. Research and Development Abliva has an extensive research and development department that constantly explores and develops new therapeutic options for rare diseases and neurological disorders. The company works closely with academic research groups, universities, and other companies to develop innovative therapies that meet the needs of patients. Clinical Trials Abliva conducts clinical trials to test the efficacy and safety of its products. These clinical trials are conducted in close collaboration with specialized research institutions and medical centers to ensure that the results are validated and trustworthy. Commercial Development Abliva aims to bring its products to market to provide patients with access to new therapies that improve their quality of life. The company has a strong partnership with Karolinska Institutet, a leading medical university in Sweden, to support its research and development activities. Summary Abliva AB is an emerging biopharmaceutical company specializing in the development of drugs for the treatment of rare diseases and neurological disorders. The company has several promising products in its pipeline that are in various stages of clinical development. Abliva works closely with academic research groups, universities, and other companies to develop innovative therapies that meet the needs of patients. The company also has a strong partnership with Karolinska Institutet, a leading medical university in Sweden, to support its research and development activities. Abliva ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/E Details
Deciphering Abliva's P/E Ratio
The Price to Earnings (P/E) Ratio of Abliva is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.
Year-to-Year Comparison
Assessing Abliva's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.
Impact on Investments
The P/E ratio of Abliva is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.
Interpreting P/E Ratio Fluctuations
Fluctuations in Abliva’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.
Frequently Asked Questions about Abliva stock
How has the price-earnings ratio of Abliva changed compared to last year?
The price-to-earnings ratio of Abliva has increased by -32.8% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Abliva high compared to other companies?
Yes, the price-to-earnings ratio of Abliva is high compared to other companies.
How does an increase in the price-earnings ratio of Abliva affect the company?
An increase in the price-earnings ratio of Abliva would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Abliva affect the company?
A decrease in the price-earnings ratio of Abliva would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Abliva?
Some factors that influence the price-earnings ratio of Abliva are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Abliva pay?
Over the past 12 months, Abliva paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Abliva is expected to pay a dividend of 0 SEK.
What is the dividend yield of Abliva?
The current dividend yield of Abliva is .
When does Abliva pay dividends?
Abliva pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Abliva?
Abliva paid dividends every year for the past 0 years.
What is the dividend of Abliva?
For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.
In which sector is Abliva located?
Abliva is assigned to the 'Health' sector.
Wann musste ich die Aktien von Abliva kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Abliva from 7/31/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 7/31/2024.
When did Abliva pay the last dividend?
The last dividend was paid out on 7/31/2024.
What was the dividend of Abliva in the year 2023?
In the year 2023, Abliva distributed 0 SEK as dividends.
In which currency does Abliva pay out the dividend?
The dividends of Abliva are distributed in SEK.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Abliva
Our stock analysis for Abliva Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Abliva Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
